Paul Richins reports 100-share sale; holds 21,136 UTMD shares post-transaction
Rhea-AI Filing Summary
Paul O. Richins, a director of Utah Medical Products, sold 100 shares of the company's common stock on 08/25/2025 at $60.34 per share. After the sale he beneficially owns 21,136 shares indirectly, held across a family trust, a personal IRA, his spouse's IRA and his sons' accounts: 18,948 shares in the Richins Family Trust, 1,245 in his spouse's IRA, 443 by his sons and 500 in his own IRA. The Form 4 indicates the filing was made by one reporting person and is signed by Mr. Richins.
Positive
- None.
Negative
- None.
Insights
TL;DR: A routine small director sale with full disclosure; holdings remain concentrated in family trust.
The reported 100-share sale at $60.34 is immaterial relative to the total beneficial holdings of 21,136 shares and appears as a routine disposition rather than a change in control or large insider divestiture. Disclosure identifies indirect ownership through a family trust and family IRAs, which keeps economic exposure concentrated within Mr. Richins' family. No amendments or other unusual disclosures are present.
TL;DR: Minor insider sale reported; transaction size and post-sale holdings indicate no material shift in insider stake.
The transaction code indicates a disposition of 100 shares on 08/25/2025 at $60.34. Post-transaction beneficial ownership is 21,136 shares held indirectly. The sale size is small relative to aggregate holdings and does not suggest a change in insider confidence or material liquidity event. All holdings and the breakdown by account type are disclosed in the filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Gift | Common Stock | 100 | $60.34 | $6K |
Footnotes (1)
- [object Object]